QR Code
Fernández-Gómez I; Sablón-Carrazana M; Bencomo-Martínez A; Domínguez G; Lara-Martínez R; Altamirano-Bustamante N; Jiménez-García L; Pasten-Hidalgo K; Castillo-Rodríguez R; Altamirano P; Marrero S; Revilla-Monsalve C; Valdés-Sosa P; Salamanca-Gómez F; Garrido-Maga a E; Rodríguez-Tanty C; Altamirano-Bustamante M (2018)

DIABETES DRUG DISCOVERY: HIAPP1–37POLYMORPHIC AMYLOID STRUCTURES AS NOVEL THERAPEUTIC TARGETS

Molecules 23(3):
full text

© 2018 by the authors. Human islet amyloid peptide (hIAPP 1–37 ) aggregation is an early step in Diabetes Mellitus. We aimed to evaluate a family of pharmaco-chaperones to act as modulators that provide dynamic interventions and the multi-target capacity (native state, cytotoxic oligomers, protofilaments and fibrils of hIAPP 1–37 ) required to meet the treatment challenges of diabetes. We used a cross-functional approach that combines in silico and in vitro biochemical and biophysical methods to study the hIAPP 1–37 aggregation-oligomerization process as to reveal novel potential anti-diabetic drugs. The family of pharmaco-chaperones are modulators of the oligomerization and fibre formation of hIAPP 1–37 . When they interact with the amino acid in the amyloid-like steric zipper zone, they inhibit and/or delay the aggregation-oligomerization pathway by binding and stabilizing several amyloid structures of hIAPP 1–37 . Moreover, they can protect cerebellar granule cells (CGC) from the cytotoxicity produced by the hIAPP 1–37 oligomers. The modulation of proteostasis by the family of pharmaco-chaperones A–F is a promising potential approach to limit the onset and progression of diabetes and its comorbidities.